Survivorship based on the classification and regression tree–selected cutoff values used to designate patients with multiple myeloma as high or low CD19+ patients at baseline and the 2-year time point
| CD19 levels3-150 . | Baseline3-151 . | 2 year3-151 . |
|---|---|---|
| Low CD19 | 2.8 | 2.2 |
| High CD19 | 4.0 | 4.4 |
| P | < .0001 | < .0001 |
| CD19 levels3-150 . | Baseline3-151 . | 2 year3-151 . |
|---|---|---|
| Low CD19 | 2.8 | 2.2 |
| High CD19 | 4.0 | 4.4 |
| P | < .0001 | < .0001 |
MM indicates multiple myeloma.
Patients with MM were subdivided into low or high CD19 subgroups based on their level of CD19+ cells being below or above the CART-detemined levels. The levels were determined separately for each patient with MM at baseline (N = 504) and at 2-year time point (N = 173).
Data is presented as survival in years from the time of CD19 cell.